Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease
Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease. Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is an independent predictor of overall mortality and cardiovascular outcome in hemodialysis...
Gespeichert in:
| Veröffentlicht in: | Kidney international 2003-12, Vol.64 (6), p.2291-2297 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2297 |
|---|---|
| container_issue | 6 |
| container_start_page | 2291 |
| container_title | Kidney international |
| container_volume | 64 |
| creator | Osanai, Tomohiro Nakamura, Masayuki Sasaki, Satoko Tomita, Hirofumi Saitoh, Masayuki Osawa, Hiroshi Yamabe, Hideaki Murakami, Shuichi Magota, Koji Okumura, K.E.N. |
| description | Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is an independent predictor of overall mortality and cardiovascular outcome in hemodialysis patients. However, not only ADMA but also traditional risk factors account for only part of the high cardiovascular morbidity and mortality in these patients. We investigated cross-sectionally the association between coupling factor 6 (CF6), an endogenous inhibitor of prostacyclin synthesis, and cardiovascular events in 95 hemodialysis patients.
Plasma CF6 level was measured by radioimmunoassay, whereas plasma ADMA level by high-performance liquid chromatography (HPLC).
Plasma levels of CF6 and ADMA were threefold higher in hemodialysis patients than in control individuals, and there was a positive correlation between these two compounds (r = 0.25, P < 0.05). Plasma CF6 level was positively correlated with serum creatinine level (r = 0.36, P < 0.01) and was reduced after dialysis (P < 0.05). Plasma CF6 and ADMA levels were both higher in hemodialysis patients complicating ischemic heart disease (myocardial infarction and/or angina) than in those free of cardiovascular events. In a multiple regression model, plasma CF6 level (r = 0.24, P = 0.023) and ADMA level (r = 0.26, P = 0.023) were independently related to the occurrence of ischemic heart disease in hemodialysis patients.
CF6 is a novel risk factor for ischemic heart disease in end-stage renal disease (ESRD). Synergism of this peptide and ADMA might contribute to its occurrence presumably by inhibition of prostacyclin and nitric oxide production. A prospective study is needed to evaluate this issue more precisely. |
| doi_str_mv | 10.1046/j.1523-1755.2003.00334.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71387403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0085253815496000</els_id><sourcerecordid>1012073851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-ae62aed42df2b9b4e22e31cd51a0c2d2d6222cb9d88a2dfa42958fb3d1cac4c43</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EotuFv4AsJLgl-CtZ5wgVUKRK7aGcrYk9KV5l7cVOtuXf1-muqMSFg-Wv5x2NniGEclZzptpP25o3QlZ80zS1YEzWZUlVP7wgq78fL8mKMd1UopH6jJznvGXl3kn2mpxx1UrJG7Ui480IeQfUxmAxTAkmHwONQ3mY96MPd3QAO8VEWwrBUQvJ-XiAbOcREsVDyWTqA92X4NP53k-_KAZX5QnukCYMMFLnM0LGN-TVAGPGt6d9TX5--3p7cVldXX__cfH5qrJq000VYCsAnRJuEH3XKxQCJbeu4cCscMK1Qgjbd05rKAwo0TV66KXjFqyySq7Jx2PdfYq_Z8yT2flscRwhYJyz2XCpN6ooW5P3_4DbOKfScTaCM85K4QXSR8immHPCweyT30H6YzgzyzjM1izWzWLdLOMwT-MwDyX67lR_7nfonoMn_wX4cAKKUhiHBMH6_Mw1QmvNdeG-HDks2g4ek8m2-LbofEI7GRf9_7t5BN12qm8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210102953</pqid></control><display><type>article</type><title>Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Osanai, Tomohiro ; Nakamura, Masayuki ; Sasaki, Satoko ; Tomita, Hirofumi ; Saitoh, Masayuki ; Osawa, Hiroshi ; Yamabe, Hideaki ; Murakami, Shuichi ; Magota, Koji ; Okumura, K.E.N.</creator><creatorcontrib>Osanai, Tomohiro ; Nakamura, Masayuki ; Sasaki, Satoko ; Tomita, Hirofumi ; Saitoh, Masayuki ; Osawa, Hiroshi ; Yamabe, Hideaki ; Murakami, Shuichi ; Magota, Koji ; Okumura, K.E.N.</creatorcontrib><description>Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is an independent predictor of overall mortality and cardiovascular outcome in hemodialysis patients. However, not only ADMA but also traditional risk factors account for only part of the high cardiovascular morbidity and mortality in these patients. We investigated cross-sectionally the association between coupling factor 6 (CF6), an endogenous inhibitor of prostacyclin synthesis, and cardiovascular events in 95 hemodialysis patients.
Plasma CF6 level was measured by radioimmunoassay, whereas plasma ADMA level by high-performance liquid chromatography (HPLC).
Plasma levels of CF6 and ADMA were threefold higher in hemodialysis patients than in control individuals, and there was a positive correlation between these two compounds (r = 0.25, P < 0.05). Plasma CF6 level was positively correlated with serum creatinine level (r = 0.36, P < 0.01) and was reduced after dialysis (P < 0.05). Plasma CF6 and ADMA levels were both higher in hemodialysis patients complicating ischemic heart disease (myocardial infarction and/or angina) than in those free of cardiovascular events. In a multiple regression model, plasma CF6 level (r = 0.24, P = 0.023) and ADMA level (r = 0.26, P = 0.023) were independently related to the occurrence of ischemic heart disease in hemodialysis patients.
CF6 is a novel risk factor for ischemic heart disease in end-stage renal disease (ESRD). Synergism of this peptide and ADMA might contribute to its occurrence presumably by inhibition of prostacyclin and nitric oxide production. A prospective study is needed to evaluate this issue more precisely.</description><identifier>ISSN: 0085-2538</identifier><identifier>EISSN: 1523-1755</identifier><identifier>DOI: 10.1046/j.1523-1755.2003.00334.x</identifier><identifier>PMID: 14633154</identifier><identifier>CODEN: KDYIA5</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Arginine - analogs & derivatives ; Arginine - blood ; asymmetric dimethylarginine ; Biological and medical sciences ; Cardiovascular Diseases - etiology ; cardiovascular event ; Chromatography, High Pressure Liquid ; coupling factor 6 ; Cross-Sectional Studies ; end-stage renal disease ; Female ; Humans ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - complications ; Male ; Medical sciences ; Middle Aged ; Mitochondrial Proton-Translocating ATPases - blood ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Oxidative Phosphorylation Coupling Factors - blood ; Radioimmunoassay ; Renal failure ; Risk Factors</subject><ispartof>Kidney international, 2003-12, Vol.64 (6), p.2291-2297</ispartof><rights>2003 International Society of Nephrology</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Dec 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-ae62aed42df2b9b4e22e31cd51a0c2d2d6222cb9d88a2dfa42958fb3d1cac4c43</citedby><cites>FETCH-LOGICAL-c479t-ae62aed42df2b9b4e22e31cd51a0c2d2d6222cb9d88a2dfa42958fb3d1cac4c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15288818$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14633154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Osanai, Tomohiro</creatorcontrib><creatorcontrib>Nakamura, Masayuki</creatorcontrib><creatorcontrib>Sasaki, Satoko</creatorcontrib><creatorcontrib>Tomita, Hirofumi</creatorcontrib><creatorcontrib>Saitoh, Masayuki</creatorcontrib><creatorcontrib>Osawa, Hiroshi</creatorcontrib><creatorcontrib>Yamabe, Hideaki</creatorcontrib><creatorcontrib>Murakami, Shuichi</creatorcontrib><creatorcontrib>Magota, Koji</creatorcontrib><creatorcontrib>Okumura, K.E.N.</creatorcontrib><title>Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease</title><title>Kidney international</title><addtitle>Kidney Int</addtitle><description>Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is an independent predictor of overall mortality and cardiovascular outcome in hemodialysis patients. However, not only ADMA but also traditional risk factors account for only part of the high cardiovascular morbidity and mortality in these patients. We investigated cross-sectionally the association between coupling factor 6 (CF6), an endogenous inhibitor of prostacyclin synthesis, and cardiovascular events in 95 hemodialysis patients.
Plasma CF6 level was measured by radioimmunoassay, whereas plasma ADMA level by high-performance liquid chromatography (HPLC).
Plasma levels of CF6 and ADMA were threefold higher in hemodialysis patients than in control individuals, and there was a positive correlation between these two compounds (r = 0.25, P < 0.05). Plasma CF6 level was positively correlated with serum creatinine level (r = 0.36, P < 0.01) and was reduced after dialysis (P < 0.05). Plasma CF6 and ADMA levels were both higher in hemodialysis patients complicating ischemic heart disease (myocardial infarction and/or angina) than in those free of cardiovascular events. In a multiple regression model, plasma CF6 level (r = 0.24, P = 0.023) and ADMA level (r = 0.26, P = 0.023) were independently related to the occurrence of ischemic heart disease in hemodialysis patients.
CF6 is a novel risk factor for ischemic heart disease in end-stage renal disease (ESRD). Synergism of this peptide and ADMA might contribute to its occurrence presumably by inhibition of prostacyclin and nitric oxide production. A prospective study is needed to evaluate this issue more precisely.</description><subject>Aged</subject><subject>Arginine - analogs & derivatives</subject><subject>Arginine - blood</subject><subject>asymmetric dimethylarginine</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular Diseases - etiology</subject><subject>cardiovascular event</subject><subject>Chromatography, High Pressure Liquid</subject><subject>coupling factor 6</subject><subject>Cross-Sectional Studies</subject><subject>end-stage renal disease</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mitochondrial Proton-Translocating ATPases - blood</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Oxidative Phosphorylation Coupling Factors - blood</subject><subject>Radioimmunoassay</subject><subject>Renal failure</subject><subject>Risk Factors</subject><issn>0085-2538</issn><issn>1523-1755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU1v1DAQhi0EotuFv4AsJLgl-CtZ5wgVUKRK7aGcrYk9KV5l7cVOtuXf1-muqMSFg-Wv5x2NniGEclZzptpP25o3QlZ80zS1YEzWZUlVP7wgq78fL8mKMd1UopH6jJznvGXl3kn2mpxx1UrJG7Ui480IeQfUxmAxTAkmHwONQ3mY96MPd3QAO8VEWwrBUQvJ-XiAbOcREsVDyWTqA92X4NP53k-_KAZX5QnukCYMMFLnM0LGN-TVAGPGt6d9TX5--3p7cVldXX__cfH5qrJq000VYCsAnRJuEH3XKxQCJbeu4cCscMK1Qgjbd05rKAwo0TV66KXjFqyySq7Jx2PdfYq_Z8yT2flscRwhYJyz2XCpN6ooW5P3_4DbOKfScTaCM85K4QXSR8immHPCweyT30H6YzgzyzjM1izWzWLdLOMwT-MwDyX67lR_7nfonoMn_wX4cAKKUhiHBMH6_Mw1QmvNdeG-HDks2g4ek8m2-LbofEI7GRf9_7t5BN12qm8</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>Osanai, Tomohiro</creator><creator>Nakamura, Masayuki</creator><creator>Sasaki, Satoko</creator><creator>Tomita, Hirofumi</creator><creator>Saitoh, Masayuki</creator><creator>Osawa, Hiroshi</creator><creator>Yamabe, Hideaki</creator><creator>Murakami, Shuichi</creator><creator>Magota, Koji</creator><creator>Okumura, K.E.N.</creator><general>Elsevier Inc</general><general>Nature Publishing</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20031201</creationdate><title>Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease</title><author>Osanai, Tomohiro ; Nakamura, Masayuki ; Sasaki, Satoko ; Tomita, Hirofumi ; Saitoh, Masayuki ; Osawa, Hiroshi ; Yamabe, Hideaki ; Murakami, Shuichi ; Magota, Koji ; Okumura, K.E.N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-ae62aed42df2b9b4e22e31cd51a0c2d2d6222cb9d88a2dfa42958fb3d1cac4c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Arginine - analogs & derivatives</topic><topic>Arginine - blood</topic><topic>asymmetric dimethylarginine</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular Diseases - etiology</topic><topic>cardiovascular event</topic><topic>Chromatography, High Pressure Liquid</topic><topic>coupling factor 6</topic><topic>Cross-Sectional Studies</topic><topic>end-stage renal disease</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mitochondrial Proton-Translocating ATPases - blood</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Oxidative Phosphorylation Coupling Factors - blood</topic><topic>Radioimmunoassay</topic><topic>Renal failure</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osanai, Tomohiro</creatorcontrib><creatorcontrib>Nakamura, Masayuki</creatorcontrib><creatorcontrib>Sasaki, Satoko</creatorcontrib><creatorcontrib>Tomita, Hirofumi</creatorcontrib><creatorcontrib>Saitoh, Masayuki</creatorcontrib><creatorcontrib>Osawa, Hiroshi</creatorcontrib><creatorcontrib>Yamabe, Hideaki</creatorcontrib><creatorcontrib>Murakami, Shuichi</creatorcontrib><creatorcontrib>Magota, Koji</creatorcontrib><creatorcontrib>Okumura, K.E.N.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Kidney international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osanai, Tomohiro</au><au>Nakamura, Masayuki</au><au>Sasaki, Satoko</au><au>Tomita, Hirofumi</au><au>Saitoh, Masayuki</au><au>Osawa, Hiroshi</au><au>Yamabe, Hideaki</au><au>Murakami, Shuichi</au><au>Magota, Koji</au><au>Okumura, K.E.N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease</atitle><jtitle>Kidney international</jtitle><addtitle>Kidney Int</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>64</volume><issue>6</issue><spage>2291</spage><epage>2297</epage><pages>2291-2297</pages><issn>0085-2538</issn><eissn>1523-1755</eissn><coden>KDYIA5</coden><abstract>Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is an independent predictor of overall mortality and cardiovascular outcome in hemodialysis patients. However, not only ADMA but also traditional risk factors account for only part of the high cardiovascular morbidity and mortality in these patients. We investigated cross-sectionally the association between coupling factor 6 (CF6), an endogenous inhibitor of prostacyclin synthesis, and cardiovascular events in 95 hemodialysis patients.
Plasma CF6 level was measured by radioimmunoassay, whereas plasma ADMA level by high-performance liquid chromatography (HPLC).
Plasma levels of CF6 and ADMA were threefold higher in hemodialysis patients than in control individuals, and there was a positive correlation between these two compounds (r = 0.25, P < 0.05). Plasma CF6 level was positively correlated with serum creatinine level (r = 0.36, P < 0.01) and was reduced after dialysis (P < 0.05). Plasma CF6 and ADMA levels were both higher in hemodialysis patients complicating ischemic heart disease (myocardial infarction and/or angina) than in those free of cardiovascular events. In a multiple regression model, plasma CF6 level (r = 0.24, P = 0.023) and ADMA level (r = 0.26, P = 0.023) were independently related to the occurrence of ischemic heart disease in hemodialysis patients.
CF6 is a novel risk factor for ischemic heart disease in end-stage renal disease (ESRD). Synergism of this peptide and ADMA might contribute to its occurrence presumably by inhibition of prostacyclin and nitric oxide production. A prospective study is needed to evaluate this issue more precisely.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>14633154</pmid><doi>10.1046/j.1523-1755.2003.00334.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0085-2538 |
| ispartof | Kidney international, 2003-12, Vol.64 (6), p.2291-2297 |
| issn | 0085-2538 1523-1755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71387403 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Arginine - analogs & derivatives Arginine - blood asymmetric dimethylarginine Biological and medical sciences Cardiovascular Diseases - etiology cardiovascular event Chromatography, High Pressure Liquid coupling factor 6 Cross-Sectional Studies end-stage renal disease Female Humans Kidney Failure, Chronic - blood Kidney Failure, Chronic - complications Male Medical sciences Middle Aged Mitochondrial Proton-Translocating ATPases - blood Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Oxidative Phosphorylation Coupling Factors - blood Radioimmunoassay Renal failure Risk Factors |
| title | Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A39%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20concentration%20of%20coupling%20factor%206%20and%20cardiovascular%20events%20in%20patients%20with%20end-stage%20renal%20disease&rft.jtitle=Kidney%20international&rft.au=Osanai,%20Tomohiro&rft.date=2003-12-01&rft.volume=64&rft.issue=6&rft.spage=2291&rft.epage=2297&rft.pages=2291-2297&rft.issn=0085-2538&rft.eissn=1523-1755&rft.coden=KDYIA5&rft_id=info:doi/10.1046/j.1523-1755.2003.00334.x&rft_dat=%3Cproquest_cross%3E1012073851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210102953&rft_id=info:pmid/14633154&rft_els_id=S0085253815496000&rfr_iscdi=true |